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Abstract 
 
Rationale A reduction of GABAergic markers in postmortem tissue is 
consistently found in schizophrenia. This is generally mediated by a decreased 
expression of the calcium-binding protein, parvalbumin (PV), and the 67-kDa 
isoform of the GABA synthesizing enzyme glutamic acid decarboxylase 
(GAD67). Similar reductions of PV or GAD67 are observed after repeated 
exposure to N-methyl-D-aspartate (NMDA) receptor antagonists but less 
attention has been paid to what occurs after their acute administration. 
Objectives Here, we have used in situ hybridization to examine the expression 
of PV and GAD67 mRNAs at 4 h and 24 h after an acute administration of MK-
801 (1 mg/kg). Results Four hours after MK-801, the expression of PV mRNA 
decreased only in dentate gyrus of the hippocampus. Twenty four hours after 
this treatment, a reduction of the levels of PV mRNA was found in the medial 
prefrontal, orbitofrontal and entorhinal cortices, hippocampus and the 
basolateral nucleus of the amygdala. In contrast, no changes in the expression 
of GAD67 were observed in any of the brain regions examined. Interestingly, the 
reduction in PV mRNA expression is observed in discrete corticolimbic 
subregions that have been implicated in schizophrenia, which is coincident with 
changes observed in postmortem tissue of schizophrenia brain. Conclusions 
These findings indicate that acute administration of a NMDA antagonist 
delineate a pattern of changes in GABAergic markers different from those 
observed in postmortem tissue in schizophrenia inasmuch as only deficits in 
parvalbumin (but not GAD67) were seen. 
 
 
Keywords 
MK-801, NMDA antagonism, Animal Model, Schizophrenia, Prefrontal cortex, 
Hippocampus, Parvalbumin, GAD67 
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Introduction 
 
 One of the most compelling findings in schizophrenia is a reduction of 
GABAergic markers in postmortem tissue. Reduced levels of the mRNA for the 
67-kDa isoform of glutamic acid decarboxylase (GAD67), the primary 
synthesizing enzyme for GABA, have been consistently found in neocortical 
regions of subjects with schizophrenia (Volk et al. 2000; Vawter et al. 2002; 
Hashimoto et al. 2003; Woo et al. 2004; Akbarian and Huang 2006). Although 
both GAD65 and GAD67 isoforms coexist in almost all GABAergic neurons in the 
brain (Esclapez et al. 1994), only exiguous changes in the expression of GAD65 
have been found in schizophrenic patients (Todtenkopf and Benes 1998). 
These changes do not appear to be generalized, but circumscribed to a subset 
of GABAergic interneurons containing the calcium-binding protein, parvalbumin 
(PV), i.e. basket and chandelier cells, that endow perisomatic and axo-axonic 
innervation of pyramidal neurons, respectively (Markram et al. 2004; Lewis et al. 
2005). Indeed, neocortical expression of PV is found also to be reduced in 
individuals with schizophrenia (Benes and Beretta 2001; Beasley et al. 2002; 
Hashimoto et al. 2003; Lewis et al. 2005). PV interneurons regulate the 
oscillatory activity in the cerebral cortex (Whittington and Traub 2003; Bartos et 
al. 2007; Sohal et al. 2009), and disruption of cortical oscillatory dynamics is 
postulated to underlie many of the neurocognitive deficits of schizophrenia (Cho 
et al. 2005; Gonzalez-Burgos and Lewis 2008). 
 In the animal setting, it is generally considered that sustained exposure to 
NMDA receptor antagonists is needed to produce a robust decrease of the 
expression of PV in rodents and monkey (Cochran et al. 2003; Rujescu et al. 
2006; Braun et al. 2007; Morrow et al. 2007). Acute administration of NMDA 
receptor antagonists including PCP, ketamine and MK-801 is also used to 
recapitulate the symptoms of schizophrenia in behavioral assays (Swerdlow et 
al. 1994; Corbett et al. 1995; Abekawa et al. 2003; Jackson et al. 2004; López-
Gil et al. 2007). For this reason it was deemed of importance to determine 
whether such treatment could also produce pathological alterations similar to 
those occurring in schizophrenia. In the present study, we have addressed this 
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 4 
issue by measuring the expression of PV and GAD67 mRNAs in brain regions 
presumed to be involved in schizophrenia, at 4 h and 24 h after a single 
injection of MK-801. 
 
Materials and Methods 
 
Animals and Treatment 
 
 Adult male Wistar rats (Charles River Laboratories, Cerdanyola del Vallès, 
Spain) weighing 275–300 g were used. Animals were maintained on a 12 h 
light/dark cycle (lights on 07:00) with unrestricted access to food and water. All 
experimental procedures followed the European Communities Council Directive 
of November 24, 1986 (86/609/EEC), and were approved by the Institutional 
Animal Care and Use Committee. MK-801 (Sigma-Aldrich, Tres Cantos, Spain) 
was dissolved in saline for intraperitoneal (i.p.) administration. The dose of MK-
801 (1 mg/kg) was chosen from previous studies that showed robust increase in 
cortical glutamate release (López-Gil et al. 2007) and injury to pyramidal 
neurons (Sharp et al. 2001), alterations that are considered to occur in 
schizophrenia. 
 
Hybridization probes 
 
 GABAergic cells were identified by the presence of the GABA synthesizing 
enzyme, GAD67. The oligonucleotides used were complementary to the bases 
1600-1653 (GenBank Accession No NM_017007). PV cells were identified by 
hybridization with oligonucleotides complementary to the bases 115-155 
(GenBank Accession No NM_022499) of PV mRNA. All oligonucleotides were 
synthesized and purified with HPLC by Isogen Bioscience BV (De Meern, The 
Netherlands). Each oligonucleotide was labeled at their 3’-end with [33P]α-dATP 
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(3000 Ci/mmol, New England Nuclear, Boston, MA) and terminal 
deoxynucleotidyltransferase (Calbiochem, San Diego, CA). Labeled probes 
were purified through ProbeQuant G-50 microcolumns (GE Healthcare, Little 
Chalfont, UK). The specificity of the autoradiographic signal obtained in the in 
situ hybridization histochemistry experiments was confirmed by performing a 
series of routine controls (Pompeiano et al. 1992). Briefly, for each of the mRNA 
under study, several oligonucleotide probes complementary to different regions 
of the same mRNA were used independently as hybridization probes in 
consecutive tissue sections showing identical pattern of hybridization. For a 
given oligonucleotide, the addition of an excess of the same unlabeled 
oligonucleotide to the hybridization solution resulted in the complete abolition of 
the specific hybridization signal. The thermal stability of the hybrids was also 
examined by washing at increasing temperatures, which resulted in a sharp 
decrease in the hybridization signal at a temperature consistent with the Tm of 
the hybrids. 
 
In Situ Hybridization Histochemistry Procedures 
 
 Rats were killed by decapitation at 4 h and 24 h after an intraperitoneal 
injection of MK-801 (1 mg/kg). The brains were then rapidly removed, frozen on 
dry ice, and stored at –80 °C. Tissue sections, 14-µm thick, were cut using a 
cryostat (HM500 OM; Microm, Walldorf, Germany), thaw mounted onto 3-
aminopropyltriethoxysilane (Sigma-Aldrich, Tres Cantos, Spain) coated slides, 
and kept at –20°C until use. The protocols for in situ hybridization 
histochemistry were based on previously described procedures (Tomiyama et 
al. 1997). Frozen tissues were brought to room temperature, air-dried and fixed 
for 20 min in 4% paraformaldehyde in phosphate-buffered saline (PBS: 2.6 mM 
KCl, 1.4 mM KH2PO4, 136 mM NaCl, 8 mM Na2HPO4). They were then washed 
once in 3·x PBS, twice in 1·x phosphate-buffered saline (PBS), 5 min each, and 
incubated in a freshly prepared solution of predigested pronase (Calbiochem, 
San Diego, CA) at a final concentration of 12 U/mL in 50 mM Tris-HCl pH 7.5 
and 5 mM EDTA for 2 min at 20°C. Proteolytic activity was stopped by 
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immersion for 30 s in 2 mg/mL glycine in 1xPBS. Tissues were rinsed in 1 x 
PBS and dehydrated in 70% and 100% ethanol for 2 min each. For 
hybridization, the radioactive probes were diluted in hybridization buffer (50% 
formamide, 4·x SSC, 1·x Denhardt’s solution, 1% sarkosyl, 10% dextran sulfate, 
20 mM phosphate buffer, pH 7, 250 µg/mL yeast tRNA and 500 µg/mL salmon 
sperm DNA) at 1–2 x 104 cpm/µL. Tissues were incubated in humid boxes 
overnight at 42 °C and then washed four times (45 min each) in 600 mM NaCl, 
10 mM Tris-HCl, pH 7.5, and 1 mM EDTA at 60°C. Hybridized sections were 
exposed to Biomax–MR (Kodak, Rochester, NY) films for 3-15 days at -70°C 
with intensifying screens. 
 
Analysis of the Results 
 
 The relative optical density (ROD) of PV and GAD67 mRNA labelings in 
different brain areas was measured by densitometry of developed films using 
the computerized image-analysis system AIS (Imaging Research Inc. St. 
Catharines, Ontario, Canada). ROD measurements were performed in triplicate 
and the values are expressed as mean ± SEM of six animals per group. 
Differences between saline- and MK-801-injected animals in the expression of 
PV and GAD67 in each of the brain structures examined were tested by 
unpaired Student’s t-test (two-tailed) followed by the Bonferroni correction for 
multiple comparisons. P < 0.05 was considered statistically significant. 
 
Preparation of the figures 
 
 Photographs of the film autoradiograms of the hybridized tissue sections 
were taken with a Wild 420 Leica microscope equipped with a digital camera 
(DXM1200 F, Nikon, Tokyo, Japan) and ACT-1 Nikon Software. Figures were 
prepared for publication using Adobe Photoshop CS3 extended software 
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(Adobe Systems, Inc., San Jose, CA, USA). Contrast and brightness of images 
were the only variables adjusted digitally. 
 
Results 
 
Distribution of PV and GAD67 in the rat brain 
 
 The densities and distribution of mRNAs for PV and GAD67 are shown in 
Figure 1. Cells containing PV mRNA can be found along different cortical areas 
with a preferential distribution within layers III and V (Figure 1, panels A1 to A4). 
As in a previous study (Tseng et al. 2008), the density of PV in the medial 
prefrontal cortex (mPFC) appeared to be higher in the dorsal than in the ventral 
part (ROD values: 0.220 ± 0.005 for prelimbic area vs. 0.170 ± 0.004 for 
infralimbic area; P < 0.002, Student’s t-test). Therefore, PV mRNA was 
measured separately in the prelimbic and infralimbic regions. A moderate 
expression of PV was also found in the basolateral nucleus of the amygdala 
(Figure 1, panel A3), hippocampal CA1/CA3 and dentate gyrus (Figure 1, 
panels A3 and A4). The greatest content of PV mRNA was observed in the 
reticular nucleus of the thalamus (Figure 1, panel A3). GAD67 mRNAs is highly 
expressed in basal ganglia (Figure 1, panels B2 and C2) and in the reticular 
nucleus of the thalamus (Fig. 1, panels B3 and C3). 
 
Effects of acute MK-801 
 
 As depicted in Figure 2A, 4 h after the systemic administration of MK-801 (1 
mg/kg) a significant reduction of the concentration of PV mRNA was found only 
in dentate gyrus (P < 0.004). However, the same effect was patent also in other 
areas of the brain 24 h later (Figure 2B), when similar reductions of PV mRNA 
were also found in the prelimbic (P < 0.05) and infralimbic (P < 0.02) areas of 
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the mPFC, the entorhinal (P < 0.05) and orbitofrontal cortices (P < 0.02), the 
dentate gyrus (P < 0.02) and CA3/CA1 (P < 0.005) subdivisions of the dorsal 
hippocampus, and the basolateral nucleus of the amygdala (P < 0.05). 
Representative pseudocolored pictures of such reductions in the mPFC, 
orbitofrontal cortex and dorsal hippocampus are depicted in Figure 3. In 
contrast, MK-801 did not change the expression of GAD67 at any of the time 
lapses examined (Figure 4). 
 
Discussion 
 
Distribution of PV and GAD67 in the rat brain 
 
 The distribution of PV and GAD67 in the brain of the rat is similar to what had 
been described in earlier studies (Esclapez et al. 1994; Feldblum et al. 1993; 
Hof et al. 1999). In the hippocampus, amygdala and the neocortex virtually all 
PV neurons are also positive for GAD67 labeling, which further confirms 
previous findings showing that neurons containing PV in these regions are 
commonly GABAergic interneurons (Kawaguchi and Kubota 1993; Freund and 
Buzsaki 1996; De Felipe 1997; Kempainen and Pitkänen 2000; McDonald and 
Mascagni 2001; Gritti et al. 2003). This also holds true for the reticular nucleus 
of the thalamus where all GABAergic neurons appear to contain PV (Celio 
1990; Arai et al. 1994; Csillik et al. 2005). 
 
Effects of acute MK-801 
 
 The main finding from the present study is that a single injection of MK-801 
was able to significantly reduce PV mRNA in discrete brain regions known to 
play a role in the pathophysiology of schizophrenia. This effect was observable 
shortly (4 h) after the administration of MK-801 only in the dentate gyrus of the 
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hippocampus, but was clearly patent in other areas of the brain 24 h later. 
Although several works have examined the effects of repeated exposure to 
NMDA antagonists on GABAergic markers in the rodent brain (Cochran et 
al.,2003; Rujescu et al. 2006; Braun et al. 2007; Morrow et al. 2007), less 
attention has been paid to such changes following acute NMDA antagonism, 
which is widely used as a pharmacological model of schizophrenia. Thus, it has 
been reported a decrease in GAD65 (but not GAD67) mRNA levels in a dose-
dependent manner in the striatum and frontal cortex of rats 3 h after the 
administration of MK-801 (Laprade and Soghomonian 1995). The preferential 
distribution of GAD65 in nerve endings suggests that it could be involved 
predominantly in the synthesis and release of vesicular GABA (Soghomonian 
and Martin 1998). Therefore, such rapid effect on GAD65 suggests that the 
changes in the expression of this isoform might be one of the earliest 
indications that the release of GABA is compromised in a subpopulation of 
GABAergic neurons after the administration of NMDA antagonists. In contrast, 
other GABAergic markers do not appear to be altered at the same time scale. 
For instance, Cochran and coworkers failed to reproduce the loss of prefrontal 
PV (as seen in schizophrenia) after a single dose of PCP (Cochran et al., 2002). 
This was probably due to the low dose of PCP used (2.58 mg/kg), together with 
the lower affinity of this antagonist (compared to that of MK-801) for the NMDA 
channel site (Wong et al., 1986). In fact, this treatment was insufficient to induce 
the synthesis of heat-shock protein 70 (Hsp 70) (Cochran et al. 2002). The 
formation of this protein is considered to be suggestive of the cellular effects 
induced by PCP and ketamine in rodents, and could also occur in schizophrenia 
(Sharp et al. 2001). With a dose of MK-801 known to induce the formation of 
Hsp 70 in the cortex of the rat (Tomitaka et al. 2000), in the present study, we 
have observed that the reduction in PV mRNA expression occurred in a 
structure-specific manner. Interestingly, this was found in discrete corticolimbic 
regions (notably in prefrontal cortex, hippocampus and basolateral amygdala) 
that have been implicated in schizophrenia (Volk et al. 2000; Beasley et al. 
2002; Hashimoto et al. 2003; Woo et al. 2004; Akbarian and Huang 2006). It 
has been previously shown that GABAergic neurons are very sensitive to 
NMDA antagonists (Grunze et al, 1996; Li et al, 2002) and is also of note from 
our results that PV cells of the dentate gyrus of the hippocampus appear to be 
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particularly responsive to the hypofunction of NMDA receptors. Further support 
for the crucial role of hippocampus in the effects of NMDA antagonists has been 
evidenced by results showing that the local administration of MK-801 in this 
structure increased the spontaneous firing rate of hippocampal neurons 
projecting directly to the mPFC (Jodo et al. 2005). Although the exact 
mechanism remains unknown, it has been proposed that NMDA antagonists 
would attenuate the tonic activation of GABA interneurons, which would result in 
a disinhibition of glutamatergic transmission (Olney and Farber, 1995; 
Moghaddam et al, 1997; Krystal et al. 2003). In addition, NMDA receptor 
hypofunction in parvalbumin-positive hippocampal interneurons impairs 
hippocampal synchrony and working memory (Korotkova et al. 2010), 
processes that are also impaired in schizophrenia and mediated by bidirectional 
interactions between the hippocampus and the mPFC (Meyer-Lindenberg et al. 
2005). In the conditions of the present study, the reduction of PV mRNA 
expression is probably a reflection of a decreased activity of such GABAergic 
interneurons, which results from NMDA blockade by MK-801. It is possible that 
the lack of any apparent change in the expression of GAD67 in the present and 
another (Laprade and Soghomonian 1995) study is accounted for by the small 
subset of interneurons affected, i.e. only those containing PV, which represents 
~25 and ~35% of total GABA neurons in mPFC and hippocampus of the rat, 
respectively (T. Romón, G. Mengod and A. Adell, unpublished results). In fact, 
alterations in GAD67 have been observed only when MK-801 was administered 
at postnatal day 7 (Coleman et al. 2009; Turner et al. 2009) or after repeated 
exposure (Qin et al. 1994). This suggests that changes in the expression of 
GAD67 could reflect adaptive changes in development and maturation of those 
cells, and that might be the reason for a single administration of MK-801 does 
not replicate the loss of GAD67 expression observed in schizophrenia. 
 In summary, acute NMDA blockade would model the decrement in the 
expression of PV, but not that of GAD67, seen in the schizophrenia brain. 
Although the changes of PV observed herein and in postmortem human tissue 
are quantitatively limited, they likely have a significant impact inasmuch as 
subtle disturbances in GABAergic cells in prefrontal cortex are now supposed to 
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be a causal part of the pathophysiology of schizophrenia (Lewis and Gonzalez-
Burgos 2008). 
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FIGURE LEGENDS 
 
Figure 1: Distribution of the mRNAs for parvalbumin (panels A1 to A4) and 
GAD67 (panels B1 to B4) in the rat brain. Abbreviations: PrL (prelimbic area), IL 
(infralimbic area), Orb (orbitofrontal cortex), RS (retrosplenial cortex), Ent 
(entorhinal cortex), VP (ventral pallidum), DG (dentate gyrus), Sub (subiculum), 
BLA (basolateral nucleus of the amygdala), VPm (ventral posteriomedial 
thalamic nucleus), and Rt (reticular nucleus of the thalamus). Scale bar, 3 mm. 
 
Figure 2: Relative optical density (ROD) of parvalbumin mRNA in different 
regions of the rat brain at 4 h (A) and 24 h (B) after the administration of MK-
801 (1 mg/kg, i.p.). ROD measurements were calculated in duplicate and the 
values are expressed as mean ± SEM of six animals per group. *P < 0.05, or 
less, comparing saline- and MK-801-injected animals (unpaired Student’s t-
test). Abbreviations: PrL (prelimbic area), IL (infralimbic area), Orb (orbitofrontal 
cortex), RS (retrosplenial cortex), Ent (entorhinal cortex), VP (ventral pallidum), 
DG (dentate gyrus), Sub (subiculum), BLA (basolateral nucleus of the 
amygdala), and Rt (reticular nucleus of the thalamus). 
 
Figure 3: Representative pseudocolored pictures of the effects of MK-801 (1 
mg/kg, i.p.) on the relative optical density (ROD) of parvalbumin (PV) mRNA 
expression. The acute administration of MK-801 (panels A2 and B2) 
significantly reduced PV mRNA in comparison with saline-injected animals 
(panels A1 and B1) in the prelimbic (PrL) and infralimbic (IL) areas of the 
prefrontal cortex, orbitofrontal cortex (Orb), CA1/CA3, dentate gyrus (DG) and 
basolateral nucleus of the amygdala (BLA). Scale bar, 3 mm. 
 
Figure 4: Relative optical density (ROD) of GAD67 mRNA in different regions of 
the rat brain at 4 h (A) and 24 h (B) after the administration of MK-801 (1 mg/kg, 
i.p.). ROD measurements were calculated in duplicate and the values are 
expressed as mean ± SEM of three animals per group. There is no significant 
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difference between saline- and MK-801-injected animals. Abbreviations as in 
Figure 2. 
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Distribution of the mRNAs for parvalbumin (panels A1 to A4) and GAD67 (panels B1 to B4) in the rat 
brain. Abbreviations: PrL (prelimbic area), IL (infralimbic area), Orb (orbitofrontal cortex), RS 
(retrosplenial cortex), Ent (entorhinal cortex), VP (ventral pallidum), DG (dentate gyrus), Sub 
(subiculum), BLA (basolateral nucleus of the amygdala), VPm (ventral posteriomedial thalamic 
nucleus), and Rt (reticular nucleus of the thalamus). Scale bar, 3 mm  
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Relative optical density (ROD) of parvalbumin mRNA in different regions of the rat brain at 4 h (A) 
and 24 h (B) after the administration of MK-801 (1 mg/kg, i.p.). ROD measurements were 
calculated in duplicate and the values are expressed as mean ± SEM of six animals per group. *P < 
0.05, or less, comparing saline- and MK-801-injected animals (unpaired Student’s t-test). 
Abbreviations: PrL (prelimbic area), IL (infralimbic area), Orb (orbitofrontal cortex), RS 
(retrosplenial cortex), Ent (entorhinal cortex), VP (ventral pallidum), DG (dentate gyrus), Sub 
(subiculum), BLA (basolateral nucleus of the amygdala), and Rt (reticular nucleus of the thalamus)  
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Representative pseudocolored pictures of the effects of MK-801 (1 mg/kg, i.p.) on the relative 
optical density (ROD) of parvalbumin (PV) mRNA expression. The acute administration of MK-801 
(panels A2 and B2) significantly reduced PV mRNA in comparison with saline-injected animals 
(panels A1 and B1) in the prelimbic (PrL) and infralimbic (IL) areas of the prefrontal cortex, 
orbitofrontal cortex (Orb), CA1/CA3, dentate gyrus (DG) and basolateral nucleus of the amygdala 
(BLA). Scale bar, 3 mm  
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Relative optical density (ROD) of GAD67 mRNA in different regions of the rat brain at 4 h (A) and 24 
h (B) after the administration of MK-801 (1 mg/kg, i.p.). ROD measurements were calculated in 
duplicate and the values are expressed as mean ± SEM of three animals per group. There is no 
significant difference between saline- and MK-801-injected animals. Abbreviations as in Figure 2  
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